Serendipity brings proprietary gene editing assets from the lab of gene editing pioneer Feng Zhang, bolstering Arbor’s diverse toolbox of novel, next-generation editors and expanding potential therapeutic applications in reverse transcriptase-based editing and insertion of large regions of DNA

Serendipity带来了基因编辑先驱张峰实验室的专有基因编辑资产，支持了Arbor多样化的新一代编辑工具箱，并扩大了基于逆转录酶的编辑和大区域DNA插入的潜在治疗应用

CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the acquisition of Serendipity Biosciences, a private biotechnology company focused on the discovery of unique gene editing technologies..

马萨诸塞州剑桥市，2024年5月8日（环球通讯社）--Arbor Biotechnologies，Inc.，一家发现和开发下一代遗传药物的生物技术公司，今天宣布收购Serendipity Biosciences，一家专注于发现独特基因编辑技术的私营生物技术公司。。

Serendipity’s novel editing technologies were discovered in the lab of leading gene editing researcher and Arbor Biotechnologies co-founder, Feng Zhang, of the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard. The innovative assets, which include Fanzor-based, IsrB-based, and additional undisclosed programmable editing technologies, complement and expand Arbor’s existing editing capabilities.

Serendipity的新型编辑技术是在领先的基因编辑研究员和Arbor Biotechnologies联合创始人张峰（Feng Zhang）的实验室中发现的，张峰是麻省理工学院麦戈文大脑研究所（McGovern Institute for Brain Research）以及麻省理工学院（Broad Institute of MIT）和哈佛大学（Harvard）的共同创始人。这些创新资产包括基于Fanzor、基于IsrB和其他未公开的可编程编辑技术，补充并扩展了Arbor现有的编辑功能。

The addition of these newly discovered nuclease technologies offers opportunities to add new therapeutic applications for Arbor’s portfolio of genomic medicines. The technologies build on the potential of CRISPR-Cas approaches by harnessing next-generation components to enhance Arbor’s RT (reverse transcriptase) editing and insertion of exons or entire genes in vivo (both all RNA-based and DNA-donor based approaches) through unique cutting properties (e.g., natural nickases), expanded genomic targeting, and smaller sizes (<500 amino acids) that enable delivery through adeno-associated virus (AAV) vectors and other size constrained delivery vehicles.

这些新发现的核酸酶技术的加入为Arbor的基因组药物组合增加了新的治疗应用提供了机会。这些技术基于CRISPR-Cas方法的潜力，利用下一代组件通过独特的切割特性（例如，天然切口酶），扩展的基因组靶向性和较小的尺寸（<500个氨基酸）来增强Arbor的RT（逆转录酶）编辑和体内外显子或整个基因的插入（所有基于RNA和基于DNA供体的方法），从而能够通过腺相关病毒（AAV）载体和其他尺寸受限的递送载体进行递送。

Financial details were not disclosed..

财务细节未披露。。

“At Arbor, we are dedicated to developing a range of small gene editing tools that enable treatment for potentially any genetic disease using any tissue specific delivery modality, including AAV. Our primary focus is on developing novel therapies for indications in the liver and CNS with significant unmet need while partnering in other areas,” said Devyn Smith, Ph.D., Chief Executive Officer of Arbor Biotechnologies.

Arbor Biotechnologies首席执行官Devyn Smith博士说：“在Arbor，我们致力于开发一系列小型基因编辑工具，使其能够使用任何组织特异性递送方式（包括AAV）治疗潜在的任何遗传疾病。我们的主要重点是为肝脏和中枢神经系统的适应症开发新的治疗方法，同时在其他领域开展合作。”。

“We are excited to add Serendipity’s innovative technologies to expand our deep toolbox of approaches for RT editing and large insertions with the potential to deliver small size next-generation precision genetic medicines in a single AAV to patients in need.”.

“我们很高兴能添加Serendipity的创新技术，以扩展我们的RT编辑和大插入方法的深层工具箱，并有可能在单个AAV中为有需要的患者提供小尺寸的下一代精确遗传药物。”。

About Arbor Biotechnologies

关于Arbor Biotechnologies

Arbor Biotechnologies® is a next-generation gene editing company based in Cambridge, MA. Combining the promise of CRISPR with advanced computational AI-driven discovery, high throughput screening, and robust protein engineering approaches, our co-founders Feng Zhang and David Walt laid the groundwork for our proprietary discovery engine, which has yielded an extensive toolbox of gene editors, far exceeding the number of editors published in the literature to date.

Arbor Biotechnologies®是一家位于马萨诸塞州剑桥的下一代基因编辑公司。结合CRISPR的承诺以及先进的计算人工智能驱动的发现，高通量筛选和强大的蛋白质工程方法，我们的联合创始人张峰和David Walt为我们的专有发现引擎奠定了基础，该引擎产生了大量的基因编辑器工具箱，远远超过了迄今为止文献中发表的编辑器数量。

We envision a future of gene editing that extends beyond simple knockdowns to include precision writing, precise excisions and large insertions. This affords us the potential to treat a broad spectrum of patients, from those with ultra-rare to the most common genetic diseases. Guided by a deep understanding of the molecular basis of disease and our access to a unique suite of optimized editors, we are rapidly advancing our discovery-stage programs with an initial focus on genomic diseases of the liver and CNS for which there are no existing functional cures.

我们设想未来的基因编辑将超越简单的敲除，包括精确的书写，精确的切除和大的插入。这为我们提供了治疗广泛患者的潜力，从极罕见的患者到最常见的遗传疾病。在对疾病分子基础的深入了解和我们获得一套独特的优化编辑器的指导下，我们正在迅速推进我们的发现阶段计划，最初的重点是肝脏和中枢神经系统的基因组疾病，目前尚无功能性治疗方法。

As we advance toward the clinic with our lead program in primary hyperoxaluria type I, we look to expand our strategic partnerships around in vivo gene editing across multiple therapeutic areas and ex vivo cell therapy programs to broaden the reach of our novel nuclease technology. For more information, please visit: arbor.bio..

随着我们在I型原发性高草酸尿症领域的领先项目走向临床，我们希望扩大我们在多个治疗领域和离体细胞治疗计划中围绕体内基因编辑的战略合作伙伴关系，以扩大我们新型核酸酶技术的范围。欲了解更多信息，请访问：arbor.bio。。